High-dose intravenous immunoglobulin in inflammatory myopathies: Experience based on controlled clinical trials

Neurological Sciences

Volumn 24, Issue SUPPL. 4, 2003, Pages

  Dalakas, M C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLACEBO; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOARCHITECTURE; DAILY LIFE ACTIVITY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; LARYNX MUSCLE; MUSCLE BIOPSY; MUSCLE CAPILLARY; MUSCLE CELL; MUSCLE STRENGTH; MYOPATHY; POLYMYOSITIS; QUANTITATIVE ANALYSIS; RASH; STATISTICAL SIGNIFICANCE; SWALLOWING; T LYMPHOCYTE ACTIVATION;

DERMATOMYOSITIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 0142186303     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-003-0090-6     Document Type: Article

References (21)

1. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 325:1487-1498
2. Engel AG, Hohlfeld R, Banker BQ (1994) The polymyositis and dermatomyositis syndrome. In: Engel AG, Franzini-Armstrong C (eds) Myology. McGraw-Hill, New York, pp 1335-1383
3. Dalakas MC, Karpati G (2001) The inflammatory myopathies. In: Karpati G, Hilton-Jones, Griggs RC (eds) Disorders of voluntary muscle (7th edn). Cambridge University Press, Cambridge, pp 636-659
4. Dalakas MC (1995) Immunopathogenesis of inflammatory myopathies. Ann Neurol 37:74-86
5. Dalakas MC (2002) Inflammatory myopathies: recent advances in pathogenesis and therapy. Adv Neurol 88:253-271
6. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993-2000
7. Dalakas MC (1996) Experience with IVIg in the treatment of inflammatory myopathies. In: Kazatchkine M, Morel (eds) Intravenous immunoglobulin research and therapy. Parthenon Publishing, UK, pp 275-284
8. Dalakas MC (1994) Intravenous immunoglobulin for dermatomyositis. N Engl J Med 330:1392-1393
9. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC (2000) Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94:99-104
10. Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94:1729-1735
11. Dalakas MC (1999) Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22:1479-1497
12. Dalakas MC (2002) Understanding the immunopathogenesis of inclusion body myositis: present and future prospects. Rev Neurol 158:948-958
13. Soueidan SA, Dalakas MC (1993) Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43:876-879
14. Amato AA, Barohn RJ, Jackson CE et al (1993) Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 43:876-879
15. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion body myositis with IVIg: a double blind, placebo-control study. Neurology 48:712-716
16. Dalakas MC, Koffman BM, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323-327
17. Walter MC, Lochmuller H, Toepfer M et al (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247:22-28
18. Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology 51 [Suppl 5]:537-545
19. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P (1991) Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients. Am J Med 91:162-168
20. Jann S, Beretta S, Moggio M, Alobbati L, Pellegrini G (1992) High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 55:60-62
21. Lang B, Laxer RM, Murphy G, Silverman ED, Roitmani CM 1991) Treatment of dermatomyositis with intravenous immunoglobulin. Am J Med 91:169-172